Published on 7 Sep 2022 on Zacks via Yahoo Finance
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More
Drug approvals and other regulatory updates are in focus in the biotech sector. The sector is also witnessing consolidation as M&A activities pick up.
Recap of the Week’s Most Important Stories:
Updates From Gilead: Gilead Sciences, Inc.’s GILD Kite announced that the European Commission (“EC”) approved its CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for the treatment of relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL). Tecartus has been approved for this indication for adult patients 26 years of age and above.